NKG2D-mediated tumor recognition and cancer immunotherapy

Takashi Morisaki, Hiroto Tanaka, Akifumi Kiyota, Norihiro Koya, Hideya Onishi, Akio Yamasaki, Hiroyuki Suzuki, Masafumi Nakamura, Mitsuo Katano

研究成果: ジャーナルへの寄稿記事

抄録

The activating receptor natural killer group 2, member D (NKG2D) and its ligands play an important role in the NK, gamma/delta T cell, and CD8 + T cell-mediated immune response to tumors. We examined the ratio and intensity of NKG2D expression before and after stimulation with IL-2 and OKT3 in ex vivo expanded lymphocytes from 29 patients who had received adoptive immunotherapy. We demonstrated that NKG2D expression rate and intensity of lymphocytes significantly increased after stimulation, and that the magnitude of NKG2D expression by activated lymphocytes was significantly correlated with prognosis. Thus, the magnitude of NKG2D expression by activated lymphocytes may correlate with the quality of clinical-grade cytotoxic T lymphocytes.

元の言語英語
ページ(範囲)40-45
ページ数6
ジャーナルBiotherapy
24
発行部数1
出版物ステータス出版済み - 1 1 2010

Fingerprint

Immunotherapy
Lymphocytes
Neoplasms
T-Lymphocytes
Adoptive Immunotherapy
Muromonab-CD3
Somatostatin-Secreting Cells
Cytotoxic T-Lymphocytes
Interleukin-2
Ligands

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

これを引用

Morisaki, T., Tanaka, H., Kiyota, A., Koya, N., Onishi, H., Yamasaki, A., ... Katano, M. (2010). NKG2D-mediated tumor recognition and cancer immunotherapy. Biotherapy, 24(1), 40-45.

NKG2D-mediated tumor recognition and cancer immunotherapy. / Morisaki, Takashi; Tanaka, Hiroto; Kiyota, Akifumi; Koya, Norihiro; Onishi, Hideya; Yamasaki, Akio; Suzuki, Hiroyuki; Nakamura, Masafumi; Katano, Mitsuo.

:: Biotherapy, 巻 24, 番号 1, 01.01.2010, p. 40-45.

研究成果: ジャーナルへの寄稿記事

Morisaki, T, Tanaka, H, Kiyota, A, Koya, N, Onishi, H, Yamasaki, A, Suzuki, H, Nakamura, M & Katano, M 2010, 'NKG2D-mediated tumor recognition and cancer immunotherapy', Biotherapy, 巻. 24, 番号 1, pp. 40-45.
Morisaki T, Tanaka H, Kiyota A, Koya N, Onishi H, Yamasaki A その他. NKG2D-mediated tumor recognition and cancer immunotherapy. Biotherapy. 2010 1 1;24(1):40-45.
Morisaki, Takashi ; Tanaka, Hiroto ; Kiyota, Akifumi ; Koya, Norihiro ; Onishi, Hideya ; Yamasaki, Akio ; Suzuki, Hiroyuki ; Nakamura, Masafumi ; Katano, Mitsuo. / NKG2D-mediated tumor recognition and cancer immunotherapy. :: Biotherapy. 2010 ; 巻 24, 番号 1. pp. 40-45.
@article{3903ec5805f1469a80c9fc2e78e30366,
title = "NKG2D-mediated tumor recognition and cancer immunotherapy",
abstract = "The activating receptor natural killer group 2, member D (NKG2D) and its ligands play an important role in the NK, gamma/delta T cell, and CD8 + T cell-mediated immune response to tumors. We examined the ratio and intensity of NKG2D expression before and after stimulation with IL-2 and OKT3 in ex vivo expanded lymphocytes from 29 patients who had received adoptive immunotherapy. We demonstrated that NKG2D expression rate and intensity of lymphocytes significantly increased after stimulation, and that the magnitude of NKG2D expression by activated lymphocytes was significantly correlated with prognosis. Thus, the magnitude of NKG2D expression by activated lymphocytes may correlate with the quality of clinical-grade cytotoxic T lymphocytes.",
author = "Takashi Morisaki and Hiroto Tanaka and Akifumi Kiyota and Norihiro Koya and Hideya Onishi and Akio Yamasaki and Hiroyuki Suzuki and Masafumi Nakamura and Mitsuo Katano",
year = "2010",
month = "1",
day = "1",
language = "English",
volume = "24",
pages = "40--45",
journal = "Biotherapy",
issn = "0914-2223",
number = "1",

}

TY - JOUR

T1 - NKG2D-mediated tumor recognition and cancer immunotherapy

AU - Morisaki, Takashi

AU - Tanaka, Hiroto

AU - Kiyota, Akifumi

AU - Koya, Norihiro

AU - Onishi, Hideya

AU - Yamasaki, Akio

AU - Suzuki, Hiroyuki

AU - Nakamura, Masafumi

AU - Katano, Mitsuo

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The activating receptor natural killer group 2, member D (NKG2D) and its ligands play an important role in the NK, gamma/delta T cell, and CD8 + T cell-mediated immune response to tumors. We examined the ratio and intensity of NKG2D expression before and after stimulation with IL-2 and OKT3 in ex vivo expanded lymphocytes from 29 patients who had received adoptive immunotherapy. We demonstrated that NKG2D expression rate and intensity of lymphocytes significantly increased after stimulation, and that the magnitude of NKG2D expression by activated lymphocytes was significantly correlated with prognosis. Thus, the magnitude of NKG2D expression by activated lymphocytes may correlate with the quality of clinical-grade cytotoxic T lymphocytes.

AB - The activating receptor natural killer group 2, member D (NKG2D) and its ligands play an important role in the NK, gamma/delta T cell, and CD8 + T cell-mediated immune response to tumors. We examined the ratio and intensity of NKG2D expression before and after stimulation with IL-2 and OKT3 in ex vivo expanded lymphocytes from 29 patients who had received adoptive immunotherapy. We demonstrated that NKG2D expression rate and intensity of lymphocytes significantly increased after stimulation, and that the magnitude of NKG2D expression by activated lymphocytes was significantly correlated with prognosis. Thus, the magnitude of NKG2D expression by activated lymphocytes may correlate with the quality of clinical-grade cytotoxic T lymphocytes.

UR - http://www.scopus.com/inward/record.url?scp=77249122272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77249122272&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:77249122272

VL - 24

SP - 40

EP - 45

JO - Biotherapy

JF - Biotherapy

SN - 0914-2223

IS - 1

ER -